Q2 2026 delivers strong commercial execution and deepening prescriber adoption, yet the real upside lies in unmet payer conversion and a maturing evidence engine.
ACOG · Earnings Call · 2026-08-13
A Quarter of Commercial Inflection
Alpha Cognition's second quarter of 2026 marked a clear inflection in the commercial trajectory of ZUNVEYL, the first new oral Alzheimer's treatment approved in over 15 years. Net product revenue reached $6.0 million, a sequential growth of 71% over Q1, driven by 8,290 bottles dispensed (+37% QoQ). The company's commercial execution is tracking "well with our expectations," according to CEO Michael McFadden, who anchored the call on the deepening adoption: "The second quarter of 2026 represents another important quarter of commercialization for ZUNVEYL." Prescriber counts climbed 27% QoQ to 1,350 HCP writers, with 76% of active prescribers placing repeat orders—a signal that the drug is moving from trial into routine practice. Facility-level penetration also widened, with 1,090 homes now ordering, and 81% of those repeating.
Q2 demand generated $6 million in net product sales, representing 71% sequential growth over Q1. That result was driven by approximately 8.29 thousand bottles up roughly 37% quarter-over-quarter.
The company's own operating income trend reflects deliberate scaling: from -$2M in early 2024 to -$8M in Q1 2026, with spend concentrated in commercial infrastructure and evidence generation. Yet management emphasizes this is intentional, framing the investment as a path to operating profitability in 2027.
Payer Access: The Missing Tailwind
The most striking disconnect is between revenue momentum and payer coverage. While demand is accelerating organically, payer engagement has not yet translated into broad formulary wins. Lauren D'Angelo, Commercial Lead, was candid: "Implementation across the downstream plan clients in Q2 was roughly consistent with Q1... The broad formulary activation we anticipated has not yet materialized at scale." This is a timing issue rather than a demand constraint—critical evidence lies in the fact that the 71% revenue growth occurred without any measurable expansion in access. As Michael noted in the Q&A, "It is not a matter of if. it is a matter of when because the payers definitely recognize the demand and the growth." The company's 74% gross-to-net (GTN) rate is expected to remain stable absent new formulary wins, but any uptick in coverage would drop straight to the bottom line, making payer conversion the single largest near-term catalyst.
Evidence Generation as the Next Catalyst
The company is building a evidence generation engine to fortify both payer discussions and prescriber confidence. The BEACON study (positive top-line results already reported), CONVERGE (retrospective analysis, top-line expected Q3 2026), and RESOLVE (prospective, data to read out mid-2027) are designed to provide real-world data in the long-term care setting—where evidence is sparse. "We anticipate top line data for Converge. in Q3 of 2026," Michael explained, highlighting its quantitative depth across the entire Alzheimer's market, including polypharmacy and adherence metrics. This complements the earlier momentum from the ZUNVEYL launch, as heard on the prior call when management discussed the “gold mine of data” — Michael McFadden, CEO · 2026-05-14 from BEACON and “the study will provide a plethora of data” — Michael McFadden, Unknown · 2026-03-26 for payers. The company is also advancing a sublingual formulation, with PK data expected in Q3—an option for the 10-20% of Alzheimer's patients with swallowing difficulties.
Financial Discipline on the Path to Profitability
Management is balancing growth with cost discipline, lowering full-year 2026 operating expense guidance to $50-54M from $54-58M. This reflects both efficiency gains and a focus on high-return spend. The company ended Q2 with $41.4M in cash, and the early settlement of the Galantos royalty obligation simplifies the capital structure. As Henry Du noted, "We believe this is a prudent use of capital a strategic step that improves the future cash flows." In the prior quarter, Michael had already set the tone: “We'll manage our expenses appropriately to move to operating profitability in 2027.” — Michael McFadden, Unknown · 2026-03-26 Net loss narrowed sequentially to -$8.8M from -$13.2M year-over-year, and the stock has responded, up 61.7% over the last 90 days. The trajectory is clear: execution is working, but the real unlock—payer adoption—remains ahead, promising a potential second leg of acceleration.